Oliver Von Richter - Sandoz | 人才画像

基本信息

Career Trajectory

Bio

Oliver von Richter currently works at Sandoz Biopharmaceuticals currently engaged in the development of biosimilars.

Research Interests

Papers共 74 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Introducing the Biosimilar Paradigm to Neurology: the Totality of Evidence for the First Biosimilar Natalizumab

Krzysztof Selmaj, Karsten Roth, Josef Höfler, Klaus Vitzithum, Rafał Derlacz,Oliver von Richter, Cyrill Hornuss,Johann Poetzl,Barry Singer, Laura Jacobs

BioDrugspp.1-13, (2024)

Cited0Views0WOSBibtex

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

Norman Gaylis,Charlotte Both,Lena Lemke,Oliver von Richter,Paul S. Yamauchi

Advances in therapy (2024)

Cited0Views0Bibtex

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

Norman Gaylis,Charlotte Both,Lena Lemke,Oliver von Richter,Paul Yamauchi

Advances in Therapyno. 5 (2024): 1-20

Cited0Views0WOSBibtex

First-in-Human, Single- and Multiple-Ascending-Dose, Food-Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy Subjects

Dirk Kropeit,Susanne Bonsmann,Oliver von Richter,David McCormick, Jorg Pausch,Melanie Sumner,Alexander Birkmann,Holger Zimmermann,Helga Ruebsamen-Schaeff

Clinical pharmacology in drug development（2023）

Cited0Views0WOSBibtex

Signal-to-noise Ratio to Assess Magnitude, Kinetics and Impact on Pharmacokinetics of the Immune Response to an Adalimumab Biosimilar

Davide Guerrieri, Matej Horvat,Jamie Fan,Jessie Wang,Lena Lemke,Oliver von Richter,Johann Poetzl

Bioanalysis (2023)

Cited0Views0WOSBibtex

Pharmacokinetic and Pharmacodynamic Similarity of Biosimilar Natalizumab (PB006) to Its Reference Medicine: a Randomized Controlled Trial

Hendrik Wessels,Oliver von Richter,Maria Velinova,Josef Hoefler,Paul Chamberlain,Arno Kromminga,Dirk Lehnick,Karsten Roth

Expert opinion on biological therapyno. 12 (2023): 1287-1297

Cited0Views0WOSBibtex

GP2017-HCF, a High Concentration Formulation, Demonstrates Similar Pharmacokinetics, Immunogenicity and Safety to GP2017, an Approved Adalimumab Biosimilar

Oliver von Richter,Terry O'Reilly, Davide Guerrieri,Jamie Fan, Constanze Fey, Steven Schussler,Fabricio Furlan,Lena Lemke

Expert opinion on biological therapy（2022）

Cited1Views0WOSBibtex

S1057 A Randomized Phase I Study Comparing Pharmacokinetics, Safety and Immunogenicity of High Concentration Formulation (100 Mg/ml) with GP2017 Formulation (50 Mg/ml), an Adalimumab Biosimilar, in Healthy Male Subjects

Juan Carlos Rondon,Oliver Von Richter, Constanze Fey,Jamie Fan,Fabricio Furlan,Lena Lemke

The American Journal of Gastroenterology（2022）

Cited0Views0Bibtex

Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis

Piotr Wiland,Andrew Blauvelt,Lena Lemke,Oliver von Richter,Alison Balfour,Fabricio Furlan,Norman Gaylis

ARTHRITIS & RHEUMATOLOGY（2021）

Cited0Views0Bibtex

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

Stanley B. Cohen,Sebastiao C. Radominski,Hideto Kameda,Alan J. Kivitz,Michael Tee,Carol Cronenberger,Min Zhang, Sarah Hackley,Muhammad I. Rehman,Oliver von Richter,Rieke Alten

BioDrugs（2020）

Cited7Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn